Search results for " cost"
Article
Innovation vs. Capacity: How CMOs Compete
…ampules
• Tendency to acquire redundant facilities from bio/pharma companies at relatively low cost and with contracts for legacy products
• Few approvals for NDA/BLAs or new active substance…
Article
Vaccine Development Faces Urgency and Challenges
Despite the proven effectiveness and value of vaccines, health agencies and insurers want lower prices, while conflicting regulations add to manufacturing costs.
For example, the transfer of produ…
Article
Fluid Handling in Biopharma Facilities
On the other hand, readdressing fluid handling capacity and functionality within an existing facility can yield substantial operational and cost benefits. Here as well, conceptual work pertaining to p…
Article
Optimization of Protein Expression in Escherichia Coli
coli has many advantages—including rapid growth, ease of scale up, and low costs—but it poses challenges as well. Here, the authors discuss some parameters that can influence protein yields and qualit…
Article
Technologies and Practices Must Evolve to Meet Demand
Process development remained the top concern for survey respondents involved in the development of cells for tissue or cell-based therapies, followed by cell stability, scale up, and costs.
Techno…
Article
Securing the Single-Use Supply Chain
Although disposable systems do provide numerous advantages, such as reduced contamination risks, shorter set-up times, and lower capital costs, biopharmaceutical manufacturers do not have that same le…
Article
Improving PAT for Biologics
“The cost for DoEs in the biopharmaceutical industry can be quite high, and DoEs can also be quite time consuming, making the use of PAT difficult. One solution may be to work with small volumes and r…
Article
New Era for Generic Drugs
Successful biosimilar development must consider manufacturing costs and quality commitments, pointed out Parexel Vice-President Cecil Nick at the September biosimilars conference sponsored by the Drug…
Article
2014 Manufacturing Trends and Outlook
Regulatory issues, costs, analytics, and inadequate bioreactor volumes were other challenges (see Table I).
Process analytical technologies
More than half of the responden…
Article
State of Quality and Compliance in the Biopharmaceutical Industry
Possibly this is because the industry's attitude has been that quality and compliance are costly, do not produce profit, and require excessive time, money, and valuable resources to attain. This minds…